Nonlinear Relationship Between Homocysteine and Mild Cognitive Impairment in Early Parkinson’s Disease: A Cross-Sectional Study

References

• Aarsland D, Kurz MW. The epidemiology of dementia associated with Parkinson disease. J Neurol Sci. 2010;289(1–2):18–22. doi:10.1016/j.jns.2009.08.034
   PubMed Web of Science ®Google Scholar
• Aarsland D, Batzu L, Halliday GM, et al. Parkinson disease-associated cognitive impairment. Nat Rev Dis Primers. 2021;7(1):47. doi:10.1038/s41572-021-00280-3
   PubMed Web of Science ®Google Scholar
• Pedersen KF, Larsen JP, Tysnes OB, Alves G. Prognosis of mild cognitive impairment in early Parkinson disease: the Norwegian ParkWest study. JAMA Neurol. 2013;70(5):580–586. doi:10.1001/jamaneurol.2013.2110
   PubMed Web of Science ®Google Scholar
• Baiano C, Barone P, Trojano L, Santangelo G. Prevalence and clinical aspects of mild cognitive impairment in Parkinson’s disease: a meta-analysis. Mov Disord. 2020;35(1):45–54. doi:10.1002/mds.27902
   PubMed Web of Science ®Google Scholar
• Poletti M, Frosini D, Pagni C, et al. Mild cognitive impairment and cognitive-motor relationships in newly diagnosed drug-naive patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2012;83(6):601–606. doi:10.1136/jnnp-2011-301874
   PubMed Web of Science ®Google Scholar
• Yarnall AJ, Breen DP, Duncan GW, et al. Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE-PD study. Neurology. 2014;82(4):308–316. doi:10.1212/WNL.0000000000000066
   PubMed Web of Science ®Google Scholar
• Yu RL, Lee WJ, Li JY, et al. Evaluating mild cognitive dysfunction in patients with Parkinson’s disease in clinical practice in Taiwan. Sci Rep. 2020;10(1):1014. doi:10.1038/s41598-020-58042-2
   PubMed Web of Science ®Google Scholar
• Kim S, Choi BY, Nam JH, Kim MK, Oh DH, Yang YJ. Cognitive impairment is associated with elevated serum homocysteine levels among older adults. Eur J Nutr. 2019;58(1):399–408. doi:10.1007/s00394-017-1604-y
   PubMed Web of Science ®Google Scholar
• Wang R, Bawa K, Feng V, et al. The relationship between homocysteine, oxidative stress, and cognition in mild cognitive impairment. Alzheimer’s Dementia. 2021;17(S5):e052381. doi:10.1002/alz.052381
   Google Scholar
• Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer’s disease. N Engl J Med. 2002;346(7):476–483. doi:10.1056/NEJMoa011613
   PubMed Web of Science ®Google Scholar
• Fan X, Zhang L, Li H, et al. Role of homocysteine in the development and progression of Parkinson’s disease. Ann Clin Transl Neurol. 2020;7(11):2332–2338. doi:10.1002/acn3.51227
   PubMed Web of Science ®Google Scholar
• Miller JW, Selhub J, Nadeau MR, Thomas CA, Feldman RG, Wolf PA. Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status. Neurology. 2003;60(7):1125–1129. doi:10.1212/01.wnl.0000055899.24594.8e
   PubMed Web of Science ®Google Scholar
• Zoccolella S, Lamberti P, Iliceto G, et al. Plasma homocysteine levels in L-dopa-treated Parkinson’s disease patients with cognitive dysfunctions. Clin Chem Lab Med. 2005;43(10):1107–1110. doi:10.1515/CCLM.2005.193
   PubMed Web of Science ®Google Scholar
• Bialecka M, Kurzawski M, Roszmann A, et al. Association of COMT, MTHFR, and SLC19A1(RFC-1) polymorphisms with homocysteine blood levels and cognitive impairment in Parkinson’s disease. Pharmacogenet Genomics. 2012;22(10):716–724. doi:10.1097/FPC.0b013e32835693f7
   PubMed Web of Science ®Google Scholar
• Perinan MT, Macias-Garcia D, Jesus S, et al. Homocysteine levels, genetic background, and cognitive impairment in Parkinson’s disease. J Neurol. 2023;270(1):477–485. doi:10.1007/s00415-022-11361-y
   PubMed Web of Science ®Google Scholar
• Sleeman I, Lawson RA, Yarnall AJ, et al. Urate and homocysteine: predicting motor and cognitive changes in newly diagnosed Parkinson’s disease. J Parkinsons Dis. 2019;9(2):351–359. doi:10.3233/JPD-181535
   PubMedGoogle Scholar
• Song IU, Kim JS, Park IS, et al. Clinical significance of homocysteine (hcy) on dementia in Parkinson’s disease (PD). Arch Gerontol Geriatr. 2013;57(3):288–291. doi:10.1016/j.archger.2013.04.015
   PubMed Web of Science ®Google Scholar
• O’Suilleabhain PE, Sung V, Hernandez C, et al. Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations. Arch Neurol. 2004;61(6):865–868. doi:10.1001/archneur.61.6.865
   PubMedGoogle Scholar
• Camicioli RM, Bouchard TP, Somerville MJ. Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson’s disease patients. Mov Disord. 2009;24(2):176–182. doi:10.1002/mds.22227
   PubMed Web of Science ®Google Scholar
• Rodriguez-Oroz MC, Lage PM, Sanchez-Mut J, et al. Homocysteine and cognitive impairment in Parkinson’s disease: a biochemical, neuroimaging, and genetic study. Mov Disord. 2009;24(10):1437–1444. doi:10.1002/mds.22522
   PubMed Web of Science ®Google Scholar
• Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30(12):1591–1601. doi:10.1002/mds.26424
   PubMed Web of Science ®Google Scholar
• Tan Y, Liu W, Du J, et al. Validation of revised Chinese version of PD-CRS in Parkinson’s disease patients. Parkinsons Dis. 2020;2020(5289136). doi:10.1155/2020/5289136
   Google Scholar
• Rosca EC, Simu M. Parkinson’s Disease-Cognitive rating scale for evaluating cognitive impairment in Parkinson’s disease: a systematic review. Brain Sci. 2020;10(9):588. doi:10.3390/brainsci10090588
   PubMed Web of Science ®Google Scholar
• Litvan I, Goldman JG, Troster AI, et al. Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: movement disorder society task force guidelines. Mov Disord. 2012;27(3):349–356. doi:10.1002/mds.24893
   PubMed Web of Science ®Google Scholar
• Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord. 2007;22(12):1689–1707. doi:10.1002/mds.21507
   PubMed Web of Science ®Google Scholar
• Pellecchia MT, Savastano R, Moccia M, et al. Lower serum uric acid is associated with mild cognitive impairment in early Parkinson’s disease: a 4-year follow-up study. J Neural Transm (Vienna). 2016;123(12):1399–1402. doi:10.1007/s00702-016-1622-6
   PubMed Web of Science ®Google Scholar
• Qu Y, Qin QX, Wang DL, et al. Estimated glomerular filtration rate is a biomarker of cognitive impairment in Parkinson’s disease. Front Aging Neurosci. 2023;15(1130833). doi:10.3389/fnagi.2023.1130833
   Google Scholar
• Huang X, Ng SY, Chia NS, et al. Higher serum triglyceride levels are associated with Parkinson’s disease mild cognitive impairment. Mov Disord. 2018;33(12):1970–1971. doi:10.1002/mds.27521
   PubMed Web of Science ®Google Scholar
• Annanmaki T, Pessala-Driver A, Hokkanen L, Murros K. Uric acid associates with cognition in Parkinson’s disease. Parkinsonism Relat Disord. 2008;14(7):576–578. doi:10.1016/j.parkreldis.2007.11.001
   PubMed Web of Science ®Google Scholar
• Wu H, Khuram RH, Li Z, et al. Correlation between serum 25(OH)D and cognitive impairment in Parkinson’s disease. J Clin Neurosci. 2022;100:192–195. doi:10.1016/j.jocn.2022.04.015
   PubMed Web of Science ®Google Scholar
• Setien-Suero E, Suarez-Pinilla M, Suarez-Pinilla P, Crespo-Facorro B, Ayesa-Arriola R. Homocysteine and cognition: a systematic review of 111 studies. Neurosci Biobehav Rev. 2016;69:280–298. doi:10.1016/j.neubiorev.2016.08.014
   PubMed Web of Science ®Google Scholar
• Bostom AG, Rosenberg IH, Silbershatz H, et al. Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: the Framingham Study. Ann Intern Med. 1999;131(5):352–355. doi:10.7326/0003-4819-131-5-199909070-00006
   PubMed Web of Science ®Google Scholar
• Streck EL, Matte C, Vieira PS, et al. Impairment of energy metabolism in hippocampus of rats subjected to chemically-induced hyperhomocysteinemia. Biochim Biophys Acta. 2003;1637(3):187–192. doi:10.1016/s0925-4439(03)00019-x
   PubMed Web of Science ®Google Scholar
• Kim YI. Folate and DNA methylation: a mechanistic link between folate deficiency and colorectal cancer? Cancer Epidemiol Biomarkers Prev. 2004;13(4):511–519. doi:10.1158/1055-9965.511.13.4
   PubMed Web of Science ®Google Scholar
• Ji Y, Lyu P, Jin W, Li X, Li X, Dong Y. Homocysteine: a modifiable culprit of cognitive impairment for us to conquer? J NEUROL SCI. 2019;404:128–136. doi:10.1016/j.jns.2019.07.015
   PubMed Web of Science ®Google Scholar
• Duan W, Ladenheim B, Cutler RG, Kruman II, Cadet JL, Mattson MP. Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson’s disease. J Neurochem. 2002;80(1):101–110. doi:10.1046/j.0022-3042.2001.00676.x
   PubMed Web of Science ®Google Scholar
• Huang CF, Wang WN, Sun CC, et al. Echinocystic acid ameliorates hyperhomocysteinemia-induced vascular endothelial cell injury through regulating NF-kappaB and CYP1A1. Exp Ther Med. 2017;14(5):4174–4180. doi:10.3892/etm.2017.5097
   PubMed Web of Science ®Google Scholar
• de Jager CA, Oulhaj A, Jacoby R, Refsum H, Smith AD. Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: a randomized controlled trial. Int J Geriatr Psychiatry. 2012;27(6):592–600. doi:10.1002/gps.2758
   PubMed Web of Science ®Google Scholar
• Smith AD, Smith SM, de Jager CA, et al. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PLoS One. 2010;5(9):e12244. doi:10.1371/journal.pone.0012244
   PubMed Web of Science ®Google Scholar
• Ma L. Depression, anxiety, and apathy in mild cognitive impairment: current perspectives. Front Aging Neurosci. 2020;12(9). doi:10.3389/fnagi.2020.00009
   Google Scholar
• Yu RL, Wu RM. Mild cognitive impairment in patients with Parkinson’s disease: an updated mini-review and future outlook. Front Aging Neurosci. 2022;14(943438). doi:10.3389/fnagi.2022.943438
   Google Scholar